In a world of overpriced biotech this is a rare bargain. Class action BS, heavy shorting and PML have conspired to create a comparative bargain. Shorts have covered over 7.5ml shares in June. Volume is up. I think this goes to new all time high on growing rev. I'm a buyer here.
Please read what I said. That is a rough upper bound, assuming that almost everything goes well. The things that have a decent chance of moving earnings within that time frame are a survival + QoL win against PC, and dramatic effects in patients with PV who are still sick despite hydroxyurea and bloodletting (things that don't need to wait for a label) Increased promise vs RA might raise confidence on that time scale, but not affect earnings substantially. Evidence strong enough to put a survival benefit on the J label can't be expected on any investment time scale.